Literature DB >> 33188281

Fra-2/AP-1 regulates melanoma cell metastasis by downregulating Fam212b.

Guang-Liang Chen1,2,3, Rui Li2,4, Xiao-Xiang Chen4, Juan Wang4, Shan Cao2,4, Rui Song2,4, Ming-Chun Zhao5, Li-Ming Li6, Nicole Hannemmann2, Georg Schett2, Cheng Qian7, Aline Bozec8.   

Abstract

Metastatic melanoma remains a challenging disease. Understanding the molecular mechanisms how melanoma becomes metastatic is therefore of interest. Herein we show that downregulation of the AP-1 transcription factor member Fra-2 in melanoma cells is associated with an aggressive melanoma phenotype in vitro and in vivo. In vitro, Fra-2 knockdown in melanoma cells promoted cell migration and invasion associated with increased Snail-1, Twist-1/2, and matrix metalloproteinase-2 (MMP-2) expression. In vivo, Fra-2 knockdown in a melanoma cell line led to increased metastasis into the lungs and liver. The increased metastatic potential of Fra-2 knockdown melanoma cells was likely due to an accelerated cell cycle transition and increased tissue angiogenesis. Using Fra-2 knockdown cell lines microarray analysis, we identified the protein Fam212b (family with sequence similarity 212 member B) as a downstream target of Fra-2. By additional knockdown of Fam212b in Fra-2 mutant cells, we mitigated the cell migration, invasion, and cell cycle transition phenotype induced by Fra-2 knockdown. Furthermore, Fam212b overexpression enhanced β-catenin pathway. Finally, Fam212b expression is correlated with increased melanoma metastasis and poor clinical outcomes in human patients. In summary, these findings reveal the Fra-2-Fam212b axis as a new pathway of melanoma metastasis, which can be in the future used as potential marker of the metastatic properties of melanoma.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33188281      PMCID: PMC8027635          DOI: 10.1038/s41418-020-00660-4

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  39 in total

Review 1.  AP-1: a double-edged sword in tumorigenesis.

Authors:  Robert Eferl; Erwin F Wagner
Journal:  Nat Rev Cancer       Date:  2003-11       Impact factor: 60.716

2.  FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma.

Authors:  Julia A Beaver; Marc R Theoret; Sirisha Mushti; Kun He; Meredith Libeg; Kirsten Goldberg; Rajeshwari Sridhara; Amy E McKee; Patricia Keegan; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2017-01-10       Impact factor: 12.531

3.  A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma.

Authors:  Julie Caramel; Eftychios Papadogeorgakis; Louise Hill; Gareth J Browne; Geoffrey Richard; Anne Wierinckx; Gerald Saldanha; Joy Osborne; Peter Hutchinson; Gina Tse; Joël Lachuer; Alain Puisieux; J Howard Pringle; Stéphane Ansieau; Eugene Tulchinsky
Journal:  Cancer Cell       Date:  2013-09-26       Impact factor: 31.743

4.  The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Authors:  Rachel Ramsdale; Robert N Jorissen; Frederic Z Li; Sheren Al-Obaidi; Teresa Ward; Karen E Sheppard; Patricia E Bukczynska; Richard J Young; Samantha E Boyle; Mark Shackleton; Gideon Bollag; Georgina V Long; Eugene Tulchinsky; Helen Rizos; Richard B Pearson; Grant A McArthur; Amardeep S Dhillon; Petranel T Ferrao
Journal:  Sci Signal       Date:  2015-08-18       Impact factor: 8.192

5.  Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility.

Authors:  Karin Milde-Langosch; Stanislava Janke; Ines Wagner; Christine Schröder; Thomas Streichert; Ana-Maria Bamberger; Fritz Jänicke; Thomas Löning
Journal:  Breast Cancer Res Treat       Date:  2007-03-28       Impact factor: 4.872

6.  During human melanoma progression AP-1 binding pairs are altered with loss of c-Jun in vitro.

Authors:  Sun Yang; Susan McNulty; Frank L Meyskens
Journal:  Pigment Cell Res       Date:  2004-02

7.  Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state.

Authors:  Annelien Verfaillie; Hana Imrichova; Zeynep Kalender Atak; Michael Dewaele; Florian Rambow; Gert Hulselmans; Valerie Christiaens; Dmitry Svetlichnyy; Flavie Luciani; Laura Van den Mooter; Sofie Claerhout; Mark Fiers; Fabrice Journe; Ghanem-Elias Ghanem; Carl Herrmann; Georg Halder; Jean-Christophe Marine; Stein Aerts
Journal:  Nat Commun       Date:  2015-04-09       Impact factor: 14.919

8.  Therapy-induced tumour secretomes promote resistance and tumour progression.

Authors:  Anna C Obenauf; Yilong Zou; Andrew L Ji; Sakari Vanharanta; Weiping Shu; Hubing Shi; Xiangju Kong; Marcus C Bosenberg; Thomas Wiesner; Neal Rosen; Roger S Lo; Joan Massagué
Journal:  Nature       Date:  2015-03-25       Impact factor: 49.962

9.  The transcriptional network for mesenchymal transformation of brain tumours.

Authors:  Maria Stella Carro; Wei Keat Lim; Mariano Javier Alvarez; Robert J Bollo; Xudong Zhao; Evan Y Snyder; Erik P Sulman; Sandrine L Anne; Fiona Doetsch; Howard Colman; Anna Lasorella; Ken Aldape; Andrea Califano; Antonio Iavarone
Journal:  Nature       Date:  2009-12-23       Impact factor: 49.962

Review 10.  Phenotype switching in melanoma: implications for progression and therapy.

Authors:  Frederic Zhentao Li; Amardeep Singh Dhillon; Robin L Anderson; Grant McArthur; Petranel T Ferrao
Journal:  Front Oncol       Date:  2015-02-13       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.